{
    "clinical_study": {
        "@rank": "132709", 
        "brief_summary": {
            "textblock": "The purpose of this research study is to determine the diurnal and nocturnal effects of\n      Travoprost with SofZia (Travatan Z) on intraocular pressure and ocular perfusion pressure.\n      We hypothesize that Travatan Z will significantly lower intraocular pressure and increase\n      ocular perfusion pressure during both the diurnal and nocturnal period, during a 24-hour\n      evaluation, compared to baseline. We further hypothesize that the medication effects will\n      persist at 72 hours after discontinuation of the drug."
        }, 
        "brief_title": "Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of open-angle glaucoma or ocular hypertension, including pigment dispersion\n             glaucoma and pseudoexfoliation glaucoma\n\n          -  Age \u2265 18 or \u2264 90 years, of either gender, or any race/ethnicity\n\n        Exclusion Criteria:\n\n          -  Females who are currently pregnant or planning to become pregnant, as determined by\n             history during the study period\n\n          -  Diagnosis of any other form of glaucoma other than open-angle\n\n          -  Schaffer angle grade < 2 in either eye by gonioscopy\n\n          -  Chronic, recurrent, or severe inflammatory eye disease\n\n          -  Intraocular surgery within 6 months or laser within 3 months\n\n          -  History of active, recurrent, or chronic ocular infection with the Herpes Simplex\n             Virus\n\n          -  History of cystoid macular edema\n\n          -  Inability to safely discontinue all ocular medications for 4 weeks\n\n          -  Patients who smoke or have irregular daily sleep patterns\n\n          -  Patients who have started or changed glucocorticoids therapy in the last 3 months\n\n          -  Patients who are currently undergoing medical marijuana therapy\n\n          -  Any use of a non-FDA approved medication for glaucoma in the last 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients diagnosed with open angle glaucoma or ocular hypertension"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779778", 
            "org_study_id": "12-0175"
        }, 
        "intervention_browse": {
            "mesh_term": "Travoprost"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aurora", 
                    "country": "United States", 
                    "state": "Colorado", 
                    "zip": "80045"
                }, 
                "name": "University of Colorado Eye Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure", 
        "overall_official": {
            "affiliation": "University of Colorado, Denver", 
            "last_name": "Leonard Seibold, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To determine the 24-hour intraocular pressure lowering effect of Travatan Z", 
            "measure": "Intraocular Pressure", 
            "safety_issue": "No", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779778"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Elucidate the duration of effect from Travatan Z administration which may lead to more efficient dosing regimens", 
            "measure": "Intraocular Pressure Change Duration", 
            "safety_issue": "No", 
            "time_frame": "72 hours"
        }, 
        "source": "University of Colorado, Denver", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Colorado, Denver", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}